Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Yuta AdachiKentaro ItoYuko HayashiRyo KimuraTuan-Zea TanRui YamaguchiHiromichi EbiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our findings suggest that EMT is a cause of both intrinsic and acquired resistance by activating the PI3K pathway in the presence of KRAS G12C inhibitor.